DE60336581D1 - Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 - Google Patents
Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68Info
- Publication number
- DE60336581D1 DE60336581D1 DE60336581T DE60336581T DE60336581D1 DE 60336581 D1 DE60336581 D1 DE 60336581D1 DE 60336581 T DE60336581 T DE 60336581T DE 60336581 T DE60336581 T DE 60336581T DE 60336581 D1 DE60336581 D1 DE 60336581D1
- Authority
- DE
- Germany
- Prior art keywords
- hpv16
- types
- vaccines against
- oncogenic hpv
- hpv18 vlps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000341655 Human papillomavirus type 16 Species 0.000 title 1
- 231100000590 oncogenic Toxicity 0.000 title 1
- 230000002246 oncogenic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43503502P | 2002-12-20 | 2002-12-20 | |
| US49665303P | 2003-08-20 | 2003-08-20 | |
| PCT/EP2003/014562 WO2004056389A1 (en) | 2002-12-20 | 2003-12-18 | Hpv-16 and -18 l1 vlp vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60336581D1 true DE60336581D1 (de) | 2011-05-12 |
Family
ID=32685362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60336581T Expired - Lifetime DE60336581D1 (de) | 2002-12-20 | 2003-12-18 | Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20060251676A1 (enExample) |
| EP (1) | EP1572233B1 (enExample) |
| JP (1) | JP5475939B2 (enExample) |
| KR (3) | KR101361769B1 (enExample) |
| AP (1) | AP2005003347A0 (enExample) |
| AR (1) | AR042530A1 (enExample) |
| AT (1) | ATE503492T1 (enExample) |
| AU (1) | AU2003293942B2 (enExample) |
| BE (3) | BE2015C068I2 (enExample) |
| BR (1) | BR0317544A (enExample) |
| CA (1) | CA2510457C (enExample) |
| CY (1) | CY1111552T1 (enExample) |
| DE (1) | DE60336581D1 (enExample) |
| DK (1) | DK1572233T3 (enExample) |
| EA (2) | EA009179B1 (enExample) |
| EC (1) | ECSP055869A (enExample) |
| IL (1) | IL169085A (enExample) |
| IS (1) | IS2811B (enExample) |
| MA (1) | MA27581A1 (enExample) |
| MX (1) | MXPA05006764A (enExample) |
| MY (1) | MY144492A (enExample) |
| NO (1) | NO20052846L (enExample) |
| NZ (1) | NZ540811A (enExample) |
| OA (1) | OA13147A (enExample) |
| PL (1) | PL215257B1 (enExample) |
| PT (1) | PT1572233E (enExample) |
| TW (1) | TWI349557B (enExample) |
| WO (1) | WO2004056389A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU750587B2 (en) * | 1998-10-16 | 2002-07-25 | Smithkline Beecham Biologicals (Sa) | Adjuvant systems and vaccines |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| PE20060434A1 (es) * | 2004-06-16 | 2006-06-08 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph |
| US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| EP1877087B1 (en) | 2005-04-15 | 2013-02-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| WO2006114312A2 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
| SG159529A1 (en) * | 2005-04-26 | 2010-03-30 | Glaxosmithkline Biolog Sa | Vaccine |
| DK2147926T3 (en) | 2007-04-29 | 2016-11-28 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | Truncated human papillomavirus type 18 L1 protein |
| US9428555B2 (en) | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
| WO2010099580A1 (en) * | 2009-03-05 | 2010-09-10 | Jenny Colleen Mccloskey | Treatment of infection |
| MX2011013566A (es) | 2009-06-19 | 2012-06-28 | Eyegene Inc | Vacunas para cancer cervical. |
| CA2938165A1 (en) | 2014-01-31 | 2015-08-06 | Ulisse Biomed S.R.L. | Biosensor for the determination of infections and associated pathologies |
| JP6663438B2 (ja) | 2014-10-24 | 2020-03-11 | エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. | 癌および皮膚病変の治療 |
| US10799574B2 (en) | 2014-10-24 | 2020-10-13 | Hpvvax. Llc | Method and composition for treating cancer or skin lesion using a vaccine |
| RU2721417C2 (ru) * | 2015-06-02 | 2020-05-19 | Терумо Кабусики Кайся | Адъювантная композиция, содержащая алюминий, и содержащая ее вакцинная композиция |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| US12404306B2 (en) * | 2018-03-06 | 2025-09-02 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| EP3812395A4 (en) * | 2018-06-04 | 2022-03-30 | Xiamen University | MUTANT OF HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4332596A1 (de) * | 1993-09-24 | 1995-03-30 | Martin Josef Dr Sapp | Monoklonale Antikörper |
| CA2302545C (en) | 1997-09-05 | 2012-04-03 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps) |
| KR20010093290A (ko) * | 1999-02-05 | 2001-10-27 | 폴락 돈나 엘. | 사람 파필로마바이러스 백신 제제 |
| US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| IL153474A0 (en) * | 2000-06-26 | 2003-07-06 | Stressgen Biotechnologies Corp | Human papilloma virus treatment |
-
2003
- 2003-12-18 KR KR1020127027784A patent/KR101361769B1/ko not_active Expired - Lifetime
- 2003-12-18 KR KR1020127026719A patent/KR20120118087A/ko not_active Withdrawn
- 2003-12-18 MY MYPI20034868A patent/MY144492A/en unknown
- 2003-12-18 AT AT03789346T patent/ATE503492T1/de active
- 2003-12-18 TW TW092135963A patent/TWI349557B/zh not_active IP Right Cessation
- 2003-12-18 US US10/540,099 patent/US20060251676A1/en not_active Abandoned
- 2003-12-18 JP JP2005502554A patent/JP5475939B2/ja not_active Expired - Lifetime
- 2003-12-18 OA OA1200500189A patent/OA13147A/en unknown
- 2003-12-18 EA EA200500834A patent/EA009179B1/ru not_active IP Right Cessation
- 2003-12-18 EA EA200701633A patent/EA200701633A1/ru unknown
- 2003-12-18 PL PL377710A patent/PL215257B1/pl unknown
- 2003-12-18 WO PCT/EP2003/014562 patent/WO2004056389A1/en not_active Ceased
- 2003-12-18 NZ NZ540811A patent/NZ540811A/en not_active IP Right Cessation
- 2003-12-18 KR KR1020057011497A patent/KR20050086924A/ko not_active Ceased
- 2003-12-18 AR ARP030104709A patent/AR042530A1/es unknown
- 2003-12-18 MX MXPA05006764A patent/MXPA05006764A/es active IP Right Grant
- 2003-12-18 DK DK03789346.8T patent/DK1572233T3/da active
- 2003-12-18 CA CA2510457A patent/CA2510457C/en not_active Expired - Lifetime
- 2003-12-18 BR BR0317544-8A patent/BR0317544A/pt not_active Application Discontinuation
- 2003-12-18 PT PT03789346T patent/PT1572233E/pt unknown
- 2003-12-18 EP EP03789346A patent/EP1572233B1/en not_active Expired - Lifetime
- 2003-12-18 AP AP2005003347A patent/AP2005003347A0/xx unknown
- 2003-12-18 AU AU2003293942A patent/AU2003293942B2/en not_active Expired
- 2003-12-18 DE DE60336581T patent/DE60336581D1/de not_active Expired - Lifetime
-
2005
- 2005-04-26 US US11/114,301 patent/US20050287161A1/en not_active Abandoned
- 2005-06-09 IS IS7885A patent/IS2811B/is unknown
- 2005-06-09 IL IL169085A patent/IL169085A/en active IP Right Grant
- 2005-06-13 NO NO20052846A patent/NO20052846L/no not_active Application Discontinuation
- 2005-06-20 EC EC2005005869A patent/ECSP055869A/es unknown
- 2005-07-18 MA MA28398A patent/MA27581A1/fr unknown
-
2011
- 2011-06-08 CY CY20111100549T patent/CY1111552T1/el unknown
-
2015
- 2015-12-09 BE BE2015C068C patent/BE2015C068I2/fr unknown
- 2015-12-09 BE BE2015C067C patent/BE2015C067I2/fr unknown
- 2015-12-09 BE BE2015C069C patent/BE2015C069I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE503492T1 (de) | Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | |
| AP1872A (en) | Virus-like particles of human papillomavirus. | |
| NO2012016I2 (no) | Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler | |
| EP1660678A4 (en) | MUTANT ADENO-ASSOCIATED VIRUS VIRUSES AND METHOD OF USE THEREOF | |
| DE60027440D1 (de) | Impfstoff gegen hbv und hpv | |
| ATE471148T1 (de) | Medizinische verwendung eines tetrahydrotriazoloä4,3-aüpyrazins | |
| LTPA2015049I1 (lt) | Žpv 45 l1 optimizuota ekspresija mielėse | |
| CY1113875T1 (el) | Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα | |
| DE602004032140D1 (de) | Behandlungsvorrichtung mit verwendung von ausgangsstoffgas und reaktivem gas | |
| DE50214263D1 (de) | Emollients und kosmetische zusammensetzungen enthaltend 2-methyl-1,3-propandioldiester | |
| HUS1500059I1 (hu) | A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina | |
| ATE358129T1 (de) | 1,2,3,4,7,8-hexahydro-6h-c1,4)diazepinoc6,7,1- 1j)chinolinderivative als antipsychotika und mittel gegen obesitas | |
| DE69933121D1 (de) | Methode, reagent und testsatz zur typisierung des genoms von papillomavirus | |
| DE50210920D1 (de) | Verwendung von Aluminiumchlorohydrat in Deodoranten und Antiperspiranten | |
| NO20055750L (no) | Nye kjemiske forbindelser | |
| SI1572233T1 (sl) | Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68 | |
| IL179138A0 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52 | |
| EP1532254A4 (en) | VIRUS-FREE HELPER HERPESVIRUS AMPLICON PARTICLES AND ITS USES | |
| DE60237181D1 (de) | Kosmetische Zusammensetzung und Methode um farbentwickelnde Zubereitungen in Kosmetika zu benutzen | |
| BR0315701B1 (pt) | composiÇço, composiÇço de tratamento na lavagem de roupas, e, uso de uma composiÇço. | |
| FI20020375A7 (fi) | Menetelmä viruksen kaltaisten partikkeleiden (VKP) tuottamiseksi, plasmidikonstrukti sekä menetelmän käytöt | |
| CY2015049I2 (el) | Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52 | |
| EP1478657A4 (en) | TETRAVALENT ANTI-ROTAVIRUS VACCINE SEQUENCE ANALYSIS | |
| DE60336275D1 (de) | Verfahren zur Herstellung von 3-(1,3-Dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als Dopamin-beta-hydroxylase Inhibitor | |
| ATE467424T1 (de) | Escape-mutanten des newcastle-disease-virus als marker-vakzine |